Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?-Reference-Cited by-同舟云学术

Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?

Published:2015-11-25 Issue:5 Volume:62 Page:552-558
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:Clin Infect Dis.

Author:

Nation Roger L.,Garonzik Samira M.,Li Jian,Thamlikitkul Visanu,Giamarellos-Bourboulis Evangelos J.,Paterson David L.,Turnidge John D.,Forrest Alan,Silveira Fernanda P.

Funder

National Institute of Allergy and Infectious Diseases (NIAID)

National Institutes of Health

NIAID

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/62/5/552/16788066/civ964.pdf

Reference31 articles.

1. SODIUM SULPHOMETHYL DERIVATIVES OF POLYMYXINS

2. Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosa

3. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections

4. Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial Infections

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. L-carnitine co-administration prevents colistin-induced mitochondrial permeability transition and reduces the risk of acute kidney injury in mice;Scientific Reports;2024-07-16

2. Antimicrobial peptides as therapeutics: Confronting delivery challenges to optimize efficacy;The Microbe;2024-03

3. Colistin plasma concentrations are not associated with better clinical outcomes in patients with pneumonia caused by extremely drug-resistant Pseudomonas aeruginosa;Microbiology Spectrum;2023-12-12

4. Pharmacokinetic/pharmacodynamic (PK/PD) simulation for dosage optimization of colistin and sitafloxacin, alone and in combination, against carbapenem-, multidrug-, and colistin-resistant Acinetobacter baumannii;Frontiers in Microbiology;2023-11-30

5. Hepatic encephalopathy: investigational drugs in preclinical and early phase development;Expert Opinion on Investigational Drugs;2023-11-02